A major Alzheimer's conference in London has placed tau therapies at the center of this week's scientific discussion, and data from Biogen's program is carrying the most anticipation. The tension is familiar to anyone who watches this space: meeting buzz runs ahead of actual numbers. Whether this readout delivers is the question the room has gathered to answer.
The London meetings
Tau has dominated the Alzheimer's conference agenda, with Biogen's program drawing the most concentrated attention, according to STAT News. Andrew Joseph, a reporter for the outlet, is covering both London meetings.
London is also hosting a pancreatic cancer conference this week, where daraxonrasib has generated scientific interest. Researchers there have been working through the drug's implications, STAT News reported.
U.S. regulatory activity
Back in the United States, the Department of Health and Human Services has begun drafting national guidance on how to safely taper SSRIs. When finalized, the guidance would give clinicians a clearer framework for managing patients coming off antidepressants. Separately, the FDA cleared a wearable injector from Sanofi for a myeloma drug, expanding administration options for patients on that therapy.
The counterargument
The counterargument is the one any experienced Alzheimer's watcher would raise: conference attention is not a verdict. Enrollment size, endpoint selection, and follow-up duration determine whether a signal holds. A clean result advances the case for tau as a therapeutic target. A muddied one reopens questions the field has been slow to close.
On balance, London has produced a genuine concentration of scientific activity this week. Biogen's tau data is the line to watch, but what matters is what the numbers say about endpoints, not what the conference floor already believes.